• 1. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 2. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

Introduction to 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine (CAS No. 1805954-05-5)

3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine, identified by its Chemical Abstracts Service Number (CAS No.) 1805954-05-5, is a specialized heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyridine family, a class of nitrogen-containing heterocycles that are widely recognized for their diverse biological activities and structural versatility. The presence of multiple functional groups, including amino groups at the 3- and 5-positions, a difluoromethyl group at the 2-position, and a trifluoromethyl group at the 6-position, endows this molecule with unique chemical properties that make it a valuable scaffold for drug discovery and development.

The structural features of 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine contribute to its potential as an intermediate in the synthesis of various pharmacologically active agents. The amino groups provide sites for further functionalization, allowing for the attachment of other pharmacophores or bioisosteres that can enhance binding affinity and selectivity. Additionally, the fluorinated substituents—specifically the difluoromethyl and trifluoromethyl groups—are well-documented in medicinal chemistry for their ability to modulate metabolic stability, lipophilicity, and binding interactions with biological targets.

In recent years, there has been a growing interest in fluorinated pyridines due to their favorable pharmacokinetic properties and improved therapeutic efficacy. The introduction of fluorine atoms into aromatic rings can lead to increased metabolic resistance, enhanced cell membrane permeability, and improved binding affinity to enzymes or receptors. For instance, studies have demonstrated that fluorinated pyridines can serve as key structural elements in kinase inhibitors, which are widely used in the treatment of cancers and inflammatory diseases. The compound’s dual amino functionality also positions it as a potential precursor for designing molecules with enhanced solubility and bioavailability.

Current research in the field of medicinal chemistry has highlighted the importance of 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine as a versatile building block for novel therapeutic agents. One notable area of investigation is its application in the development of small-molecule inhibitors targeting protein-protein interactions (PPIs). PPIs play crucial roles in numerous cellular processes, making them attractive therapeutic targets. However, their large surface areas and lack of well-defined binding pockets present significant challenges for drug design. Fluorinated pyridines have shown promise in modulating PPIs by interacting with specific residues or by influencing hydrophobic interactions within the binding interface.

Moreover, recent advances in computational chemistry and molecular modeling have facilitated the rational design of fluorinated pyridines with optimized pharmacological profiles. These computational approaches allow researchers to predict how structural modifications will affect biological activity, enabling the rapid screening of virtual libraries before experimental synthesis. The incorporation of machine learning algorithms has further accelerated this process by identifying promising candidates based on patterns observed in large datasets. As a result, 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine has emerged as a compound of interest for high-throughput screening campaigns aimed at discovering novel drug candidates.

The synthesis of 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine involves multi-step organic transformations that require careful optimization to ensure high yield and purity. Common synthetic routes include nucleophilic substitution reactions on halogenated pyridines followed by functional group interconversions. The use of protecting groups is often necessary to prevent unwanted side reactions during synthesis. Given its complex structure, advanced synthetic methodologies such as transition-metal-catalyzed cross-coupling reactions may be employed to construct key carbon-carbon bonds efficiently.

In addition to its pharmaceutical applications, 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine has shown potential in materials science research. Fluorinated heterocycles are known for their thermal stability and electronic properties, making them suitable candidates for organic semiconductors or liquid crystal displays (LCDs). The presence of multiple fluorine atoms can influence electron delocalization within the molecule, affecting its conductivity or luminescent characteristics. Such applications are particularly relevant in the development of next-generation electronic devices where performance demands are continuously increasing.

Evaluation of 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine in preclinical studies has provided insights into its biological activity and potential therapeutic utility. Initial assays have revealed moderate inhibition against certain kinases and enzymes associated with metabolic disorders. While these findings are promising, further investigation is required to fully elucidate its mechanism of action and assess its safety profile. Collaborative efforts between academic institutions and pharmaceutical companies are essential to translate these preliminary results into clinical trials where efficacy can be rigorously tested.

The regulatory landscape for novel chemical entities like 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine is governed by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory bodies require comprehensive data on chemical synthesis, physicochemical properties, toxicology studies, and manufacturing processes before approving new drugs or intermediates for use. Compliance with Good Manufacturing Practices (GMP) ensures that all materials used in drug development meet stringent quality standards.

Future directions in research may explore derivatization strategies that enhance the pharmacological properties of 3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine through structural modifications such as introduction of additional heteroatoms or bioisosteres. Advances in green chemistry principles could also influence synthetic methodologies by reducing waste generation or minimizing hazardous reagent usage—a critical consideration given increasing environmental regulations worldwide.

In conclusion,3,5-Diamino-2-(difluoromethyl)-6-(trifluoromethyl)pyridine (CAS No. 1805954-05-5) represents a significant compound within pharmaceutical chemistry due to its unique structural features and potential applications across multiple therapeutic areas including oncology,microbiology,and metabolic diseases.Later-stage research will focus on optimizing synthetic routes,bioconjugation techniques,and preclinical validation inorder to realize its full therapeutic potential while adheringto regulatory standards.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)